Topotecan in the First-Line Treatment of Small-Cell Lung Cancer

Publisher： Karger

E-ISSN： 2296-5262|23|3|13-17

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.23, Iss.3, 2000-05, pp. : 13-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Topotecan/Taxol in First-Line Small-Cell Lung Cancer: Where Is the Benefit?

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 7-8

Karger

Access to resources Recommend Favorite

Status of Topotecan in Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 3, 2000-05 ,pp. : 1-1

Karger

Access to resources Recommend Favorite

Topotecan (Hycamtin®) in the Therapy of Small-Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1999-01 ,pp. : 13-17

Karger

Access to resources Recommend Favorite

Phase I Dose Escalation Study of Carboplatin to a Fixed Dose of Irinotecan as First-Line Treatment of Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 280-284

Karger

Access to resources Recommend Favorite

First-Line Therapy of Mutated Non-Small Cell Lung Cancer: An Update

By  

Oncology Research and Treatment, Vol. 35, Iss. 5, 2012-04 ,pp. : 293-299

Karger

Access to resources Recommend Favorite